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Abstract 
Objective: We evaluated reporting completeness and transparency in randomized controlled trials (RCTs) conducted using administra- 
tive data based on 2021 CONSORT Extension for Trials Conducted Using Cohorts and Routinely Collected Data (CONSORT-ROUTINE) 
criteria. 
Study Design and Setting: MEDLINE and the Cochrane Methodology Register were searched (2011 and 2018). Eligible RCTs 
used administrative databases for identifying eligible participants or collecting outcomes. We evaluated reporting based on CONSORT- 
ROUTINE, which modified eight items from CONSORT 2010 and added five new items. 
Results: Of 33 included trials (76% used administrative databases for outcomes, 3% for identifying participants, 21% both), most 
were conducted in the United States (55%), Canada (18%), or the United Kingdom (12%). Of eight items modified in the extension; six 
were adequately reported in a majority ( > 50%) of trials. For the CONSORT-ROUTINE modification portion of those items, three items 
were reported adequately in > 50% of trials, two in < 50%, two only applied to some trials, and one only had wording modifications 
and was not evaluated. For five new items, four that address use of routine data in trials were reported inadequately in most trials. 
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Conclusion: How administrative data are used in trials is often sub-optimally reported. CONSORT-ROUTINE uptake may im- 
prove reporting. © 2021 The Author(s). Published by Elsevier Inc. This is an open access article under the CC BY license 
( http:// creativecommons.org/ licenses/ by/ 4.0/ ) 


















































What is new? 
Key Findings 
• Among items modified from the 2010 CONSORT 
statement, items on describing the use of an ad- 
ministrative database in the abstract (91%), includ- 
ing the administrative dataset in the statement of 
trial design (82%), and describing the source of 
outcome data (88%) were adequately reported in 
most trials; modifications related to how the use 
of administrative data may have influenced gener- 
alizability (21%) and funding of the database (6%) 
were not reported adequately in most trials. 
• New CONSORT-ROUTINE items on eligibility cri- 
teria for inclusion in the administrative database 
(6% adequate, 21% partially adequate), description 
of record linkages (3%, 33%), listing of codes and 
adjudication of outcomes (0%, 15%), and provid- 
ing a full description of the administrative database 
(9%, 82%) were not reported adequately in most 
trials. 
What this study adds to what was known? 
• No previous studies have examined completeness 
and transparency of reporting of recent random- 
ized controlled trials conducted using administra- 
tive databases published prior to the development 
of the CONSORT-ROUTINE statement. 
What is the implication and what should change 
now? 
• The way in which administrative data are used in 
trials is often not reported adequately and may re- 
duce utility of published trial reports. 
• Authors should refer to the 2021 CONSORT Exten- 
sion for Trials Conducted Using Cohorts and Rou- 
tinely Collected Data (CONSORT-ROUTINE) for 
guidance on reporting of trials conducted using co- 
horts, registries, electronic health records, and ad- 
ministrative databases. 
1. Introduction 
There is growing interest in the use of administrative
databases to evaluate health care interventions [1] . Health
system administrative databases include information col-Please cite this article as: M. Imran et al., Reporting transparency and complete
do not adequately report elements related to use of databases, Journal of Clinilected for administrative or billing purposes (e.g., Medicare
data in the United States) that is routinely collected during
clinic, hospital, laboratory, or pharmacy visits. These data
can provide a readily available source of “real-world” data
on a large population over expansive geographic regions
[2] . Administrative databases are increasingly accessible
to researchers and are being more frequently utilized in
randomized controlled trials (RCTs) as an inexpensive and
reliable resource of data at multiple stages of trials, from
identifying and recruiting eligible participants to determin-
ing study outcomes [ 3 , 4 ]. 
There are several possible advantages of using adminis-
trative data to conduct RCTs, such as more efficient iden-
tification and recruitment of participants, improved data
collection and outcome ascertainment, and improved fea-
sibility due to reductions in cost, time, and resources
[5] . However, several factors must be considered in these
types of RCTs. For instance, the accuracy of adminis-
trative data and potential for bias should be taken into
account if complete data are not available for all poten-
tial trial participants. Many large administrative databases
have been developed by governments and private insur-
ers, primarily for financial and administrative purposes,
rather than clinical research, and therefore vary in com-
pleteness and accuracy [ 3 , 6 , 7 ]. Characteristics of partic-
ipants in an administrative database used to select trial
participants and how well they match the true target pop-
ulation for the trial should be taken into consideration be-
cause the representativeness of trial participants is depen-
dent on that of the administrative database. In addition,
there may be unique challenges in linking administrative
data to other sources of data, stemming, for example, from
linkage errors when records cannot be linked or are linked
incorrectly [8] . 
The CONsolidated Standards of Reporting Trials (CON-
SORT) 2010 reporting guideline, which includes a 25-item
checklist and flow diagram, was developed to improve the
quality of reporting of parallel group RCTs [9] . Several
extensions of the CONSORT Statement have been devel-
oped to encourage better reporting of alternative trial de-
signs, including multiarm parallel group randomized trials
[10] , cluster trials [11] , pilot and feasibility trials [12] , and
pragmatic trials [13] , for example. CONSORT-ROUTINE,
which was published in 2021, was developed as an exten-
sion for trials conducted using cohorts and routinely col-
lected data, including registries, electronic health records,
and administrative data, and provides a minimal set of
items that should be included in reports of these typesness in trials: Paper 3 – trials conducted using administrative databases 
cal Epidemiology, https:// doi.org/ 10.1016/ j.jclinepi.2021.09.010
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of trials [14] . CONSORT-ROUTINE was needed because,
although RCTs conducted using cohorts and routinely col-
lected data share elements with two-arm parallel groups
RCTs covered in the CONSORT 2010 statement, there are
aspects that differ and require additional or modified re-
porting elements. 
The present review examines RCTs identified as part
of a broader scoping review [15] that was conducted to
support the development of CONSORT-ROUTINE [14] .
We aimed to (1) describe characteristics of RCTs con-
ducted using administrative data and published after the
CONSORT 2010 statement; and (2) assess and describe
the quality of reporting of trials using administrative data
by coding the completeness and transparency of all newly
added and modified items from CONSORT-ROUTINE. For
modified items, we also evaluated the transparency and
completeness of reporting of the CONSORT 2010 items
to determine if any suboptimal reporting was specific to
the extension or if reporting was deficient even based on
the CONSORT 2010 checklist item available at the time
of publication. Since CONSORT-ROUTINE was published
in 2021, the present study serves as a benchmark for pre-
CONSORT-ROUTINE reporting of trials conducted using
administrative databases. 
2. Methods 
The study protocol is accessible via the Open Science
Framework: https:// osf.io/ dp23x/ . 
2.1. Inclusion and exclusion criteria for RCTs using 
administrative databases 
The main scoping review included reports of trials that
had used cohorts or routinely collected data to both identify
or screen for participants and ascertain trial outcomes, as
well as protocols, commentaries, and reviews of method-
ological aspects of conducting trials using cohorts or rou-
tinely collected data [15] . For the present review, eligi-
ble RCTs had to have used an administrative database to:
(1) identify potentially eligible participants for the trial;
(2) ascertain trial outcomes; or (3) both. Administrative
databases were defined as databases not originally intended
for research that are used for routine governance and pro-
gram administration. Some examples include public or pri-
vate insurance databases, birth or death registries, or em-
ployment and social care databases. 
Methodological reviews, commentaries, and trial pro-
tocols were excluded. Publications that reported cost-
effectiveness studies or RCTs assessing non-health out-
comes were also excluded. Although the main scoping re-
view searched for publications from 2007 to 2018, we re-
stricted the present review to trials published from 2011 to
2018 to include only those published following the publi-
cation of the CONSORT 2010 statement. Please cite this article as: M. Imran et al., Reporting transparency and complete
do not adequately report elements related to use of databases, Journal of Clini2.2. Search strategy and study selection 
Ovid MEDLINE Epub Ahead of Print, In-Process &
Other Non-Indexed Citations, Ovid MEDLINE Daily and
Ovid MEDLINE and EBM Reviews – Cochrane Method-
ology Registry (Final issue, third Quarter 2012) were
searched from January 2007 to March 2018 (Cochrane
Methodology Register up to last update in July 2012).
Search strategies were developed by an experienced re-
search librarian familiar with knowledge synthesis related
to research methods and reporting with input from the
project team and were peer reviewed using the Peer Re-
view of the Electronic Search Strategy (PRESS) [16] .
Appendix 1 provides search terms used to identify RCTs
conducted using administrative data. References were im-
ported into Refworks, and duplicates were removed. Refer-
ences were then imported into the systematic review soft-
ware DistillerSR (Evidence Partners, Ottawa, Canada) [17] .
The coding manual for inclusion and exclusion is shown
in Appendix 2 . 
Titles and abstracts were screened independently by two
reviewers. A liberal accelerated method, where titles and
abstracts are screened by one reviewer and excluded pub-
lications are screened by a second reviewer, was used to
identify publications for inclusion for full text review [18] .
This was done in random order so that reviewers were
blind to whether the other reviewer had already made a
decision on any given title and abstract. Any trial that ap-
peared potentially eligible was selected for full-text review,
even if administrative database use was not described ex-
plicitly in the abstract. Full texts were screened indepen-
dently by two reviewers, and any disagreements were re-
solved by discussion and consensus with involvement of a
third reviewer, if necessary. 
2.3. Data extraction 
Data were extracted from all identified studies into a
predefined form. Items extracted from each RCT publica-
tion included: research question of the trial, level of ran-
domisation (cluster, individual), setting, disease of inter-
est, use of administrative database (participant identifica-
tion, trial data collection), intervention (surgical, screening,
drug, other), comparator (placebo, active comparison, usual
care), primary outcome, whether primary outcome was as-
sessed using the administrative database, country where
the RCT was conducted, and the number of clusters or
participants randomized. These items were presented for
all trials and separately by cluster RCTs and individually
randomized RCTs. We also classified studies into reports
of primary or secondary trial outcomes to evaluate any dif-
ferences in the quality of reporting between primary and
secondary reports. Primary publications were defined as
reports on the trial’s primary outcome(s) and also, pos-
sibly, other trial outcomes. Secondary publications were
defined as reports on only secondary outcomes or otherness in trials: Paper 3 – trials conducted using administrative databases 
cal Epidemiology, https:// doi.org/ 10.1016/ j.jclinepi.2021.09.010
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post-hoc outcomes; reports that described reporting sec-
ondary outcomes or that referred to a previous publication
of trial outcomes were coded as secondary reports. 
Data were extracted by one investigator and validated
by a second investigator. 
2.4. Evaluation of completeness and transparency of 
reporting 
We evaluated the completeness and transparency of all
items in CONSORT-ROUTINE that were either new items
(N = 5) or were items from the CONSORT 2010 state-
ment [14] that were modified (N = 8). For modified items,
we evaluated reporting both based on the original CON-
SORT 2010 items and based on the modified portion of
the items. We did this in order to determine if any subop-
timal reporting was related to inadequate reporting based
on the original CONSORT 2010 checklist item, which was
available at the time of publication of the included trials,
or to the item modification. We did not evaluate reporting
of items that were unmodified from the CONSORT 2010
statement. 
For each included trial, reporting of each item was cat-
egorized as ‘adequately reported’, ‘partially reported’, ‘in-
adequately or not reported’, or ‘not applicable’. A coding
manual was devised to ensure consistent assessment of re-
porting (see Appendix 3 ). This manual was also used in
separate studies that assessed the completeness and trans-
parency of reporting in registries and electronic health
records [ 19 , 20 ]. The data extraction rules and coding man-
ual were pilot tested in five RCTs by four investigators to
clarify wording and calibrate agreement between review-
ers. The assessment of completeness and transparency of
reporting was then conducted by one reviewer and vali-
dated by a second reviewer. Any disagreements were re-
solved by discussion and consensus with a third reviewer
consulted as necessary. Results were synthesized by to-
talling the number and percentage of studies adequately,
partially, and inadequately or not applicable for each item.
3. Results 
We retrieved 660 unique citations from the electronic
database search, of which 509 were excluded after title
and abstract review and 118 after full-text review, leaving
33 publications for data extraction and quality assessment.
See Figure 1 . References for all includes studies are in
Appendix 4 . 
3.1. Characteristics of included RCTs 
Of the 33 included studies, 25 (76%) were primary pub-
lications, and eight (24%) were secondary publications; 20
(61%) were individually randomized, and 13 (39%) were
cluster RCTs. There were 25 (76%) that used administra-
tive databases to assess outcomes only, seven (21%) thatPlease cite this article as: M. Imran et al., Reporting transparency and complete
do not adequately report elements related to use of databases, Journal of Cliniused them for both participant identification and outcome
assessment, and one (3%) that used them for identification
of participants only. 
Most trials were performed in the United States
(N = 18, 55%), followed by Canada (N = 6, 18%) and
the United Kingdom (N = 4, 12%). The interventions most
frequently tested were educational (N = 10, 30%), multi-
component (N = 7, 21%), and drugs (N = 4, 12%). Com-
parators included usual care (N = 25, 76%) and alterna-
tive therapies (N = 8, 24%). Commonly reported primary
outcomes were mortality (N = 5, 15%), hospitalization
(N = 5, 15%), and surrogate outcomes (N = 4, 12%). Of
the 33 included studies, 22 (67%) used the administrative
database for ascertaining the primary trial outcome and 10
(30%) for ascertaining secondary outcomes; for one trial
(3%) it was unclear whether primary or secondary out-
comes were ascertained (see Table 1 and Appendix 5 for
table by cluster versus individually randomized trials). 
3.2. Baseline assessment of completeness and 
transparency of reporting 
Results for all included trials are available at https://osf.
io/ hs9tz/ . 
3.2.1. CONSORT 2010 items with modifications in 
CONSORT-ROUTINE 
Eight CONSORT 2010 items were modified in
CONSORT-ROUTINE. As shown in Table 2 , the origi-
nal version of six of these items (“Structured summary”
(88%), “Eligibility criteria” (85%), “Outcome definition”
(94%), “Participant flow” (67%), “Interpretation” (97%)
and “Funding” (58%)) were adequately reported in a ma-
jority of trials ( Table 2 ). Item “Trial design” was ade-
quately reported in 39%, and Item “Allocation concealment
mechanism” was adequately reported in 27%. Compliance
to the CONSORT 2010 criteria was generally similar in
primary and secondary publications (see Appendix 6 ). 
In the modified portions of the modified items, three
items were adequately reported in a majority of trial pub-
lications; (“Modified – Administrative database use and
name in the abstract” (91%), “Modified – Description of
trial design” (82%) and “Modified – Outcomes” (88%)).
One item “Modified – Funding” was adequately reported
for only 6% but partially reported for 61%. Another, “Mod-
ified – Interpretation of results”, was reported adequately
in only 21%. The remaining two items were not applica-
ble for assessment in a majority of trials because the tri-
als used administrative data for assessing outcomes only,
but not for identifying eligible participants or as a mech-
anism for allocating participants to trial arms: (“Modified
– Eligibility criteria for participants” (82%) and “Modified
– Participant flow” (84%)). Item “Modified – Allocation
concealment” was not coded separately as the modifica-
tion was a clarification of the original item. Results wereness in trials: Paper 3 – trials conducted using administrative databases 
cal Epidemiology, https:// doi.org/ 10.1016/ j.jclinepi.2021.09.010
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similar when stratified by primary and secondary publica-
tion type ( Appendix 6 ). 
3.2.2. New items in CONSORT-ROUTINE 
Of the five new items evaluated, four items were inade-
quately reported in > 50% of trials; “Eligibility (for cohort
or routinely collected database)” (73%), “Description of
record linkage” (64%) and “List of codes, monitoring and
adjudication for outcomes” (82%). Item “Description of the
cohort or routinely collected database” was adequately re-
ported in only 9% but partially reported in 82%. Only one
item “Informed consent” (79%) was adequately reported
in most of the trials. 
4. Discussion 
We evaluated the degree to which 33 RCTs conducted
using administrative data reported results consistent with
existing CONSORT reporting criteria and with new crite-
ria in CONSORT-ROUTINE [14] . Among eight modified
items, seven included additional content in the modifica-
tion. Based on the CONSORT 2010 versions of the eight
items, six items related to elements of trial design, in-
terpretation, and funding were adequately reported in atPlease cite this article as: M. Imran et al., Reporting transparency and complete
do not adequately report elements related to use of databases, Journal of Clinileast 50% of included trials, but two items related to ran-
domisation and allocation methodology were not typically
reported adequately. Considering only the modified parts
of the seven items with additional content, three items re-
lated to describing that routinely collected data were used
in the abstract, including the administrative dataset in the
statement of the trial design, and describing the source of
outcome data were adequately reported in a majority of the
trials. Modifications related to interpreting how the use of
routinely collected data may have influenced the trial or
its generalizability and reporting funding of the routinely
collected database were not reported adequately in most
trials. Two items with modifications were not evaluated in
most trials because they were only applicable to trials that
used administrative databases for purposes other than as-
sessing outcomes (e.g., eligibility, recruitment, allocation).
Among the five new items, four related to aspects of using
the routinely collected data were not reported adequately
in most trials, whereas one item that requires reporting of
aspects of consent was adequately reported in more than
50% of trials. 
Among key reporting gaps, most studies did not ade-
quately describe the administrative database used in the
RCT, which is important for assessing the validity of theness in trials: Paper 3 – trials conducted using administrative databases 
cal Epidemiology, https:// doi.org/ 10.1016/ j.jclinepi.2021.09.010
6 M. Imran et al. / Journal of Clinical Epidemiology xxx (xxxx) xxx 
ARTICLE IN PRESS 
JID: JCE [mNS; October 14, 2021;20:47 ] 
Table 1. Characteristics of trials conducted using administrative databases 
Total (%) 
(n = 33) 
Primary publication (versus secondary) 25 (76%) 
Use of administrative data in trial 
Identification of patients 1 (3%) 
Outcome ascertainment 25 (76%) 
Both identification and outcomes 7 (21%) 
Administrative data used for primary outcome (versus no or unclear) 22 (67%) 
Setting 
Inpatient 11 (33%) 
Primary care 10 (30%) 
Other I 12 (36%) 
Country 
USA 18 (55%) 
Canada 6 (18%) 
UK 4 (12%) 
Other II 2 (6%) 
Disease type 
General health 12 (36%) 
Cardiovascular disease 9 (27%) 
Other III 12 (36%) 
Intervention 
Educational 10 (30%) 
Multicomponent 7 (21%) 
Drug 4 (12%) 
Other IV 12 (36%) 
Active comparator (versus usual care) 8 (24%) 
Primary outcome 
Mortality 5 (15%) 
Hospitalization 5 (15%) 
Surrogate 4 (12%) 
Other V 19 (58%) 
Sample size 
Clusters (Median and IQR) in 13 cluster randomised trials 101 
[73–221] 
Participants (Median and IQR) in 13 cluster randomised trials 119,910 
[86,998–526,850] 
Participants (Median and IQR) in 20 individually randomised trials 32,804 
[32,804–33,081] 
I Community medicine, outpatient, residential setting, multiple settings. 
II Europe, Australia, India, New Zealand. 
III Mental health, respiratory disease, diabetes, cancer, potentially inapproproate medicines, drug side effects, infection, disability, home- 
lessness. 
IV Guideline/reminder-based, elephone/web-based care, Family Finding program, referral, housing, health care provider support, surgical. 
V Self-reported, insurance claims, uptake of treatment, disease occurence, no primary outcome, adherence, risk of injury, multiple/composite 









data used and may have implications for trial generaliz-
ability. Information related to database eligibility criteria
was also inadequately reported, which could negatively
affect the ability of readers to judge the representative-Please cite this article as: M. Imran et al., Reporting transparency and complete
do not adequately report elements related to use of databases, Journal of Clininess of the database to the population targeted for the
RCT intervention. Details on linkage methodology between
databases, which can add biases due to incomplete or in-
correct matching of participants, was also poorly reportedness in trials: Paper 3 – trials conducted using administrative databases 


























































Table 2. Completeness and transparency of reporting for CONSORT 2010 items that were modified, modified items, and new items in CONSORT-ROUTINE I 













Title and abstract 
1b Structured summary of trial design, 
methods, results, and conclusions (for 
specific guidance see CONSORT for 
abstracts). 
29 (88%) 4 (12%) 0 (0%) - 
Structured summary of trial design, methods, 
results, and conclusions (for specific guidance 
see CONSORT for abstracts). Specify that a 
cohort or routinely collected data were used to 
conduct the trial and, if applicable, provide the 
name of the cohort or routinely collected 
database(s) (Modified) 
30 (91%) 3 (9%) 0 (0%) - 
Methods 
Trial design 3a Description of trial design (such as 
parallel, factorial) including allocation 
ratio 
11 (33%) 9 (27%) 13 (39%) - 
Description of trial design (such as parallel, 
factorial) including allocation ratio, that a cohort 
or routinely collected database(s) was used to 
conduct the trial (such as electronic health record, 
registry) and how the data were used within the 
trial (such as identification of eligible trial 
participants, trial outcomes) (Modified) 
27 (82%) 6 (18%) 0 (0%) - 
Cohort or routinely 
collected database 
ROUTINE-1 Name, if applicable, and description of the 
cohort or routinely collected database(s) used to 
conduct the trial, including information on the 
setting (such as primary care), locations, and 
dates, (such as periods of recruitment, 
follow-up, and data collection) (New) 
3 (9%) 27 (82%) 3 (9%) - 
ROUTINE-2 Eligibility criteria for participants in the cohort 
or routinely collected database(s) (New) 
2 (6%) 7 (21%) 24 (73%) - 
ROUTINE-3 State whether the study included person-level, 
institutional-level, or other data linkage across 
two or more databases and, if so, linkage 
techniques and methods used to evaluate 
completeness and accuracy of linkage (New) 
1 (3%) 11 (33%) 21 (64%) - 













































































































Table 2 ( continued ) 













Trials participants 4a Eligibility criteria for participants 28 (85%) 4 (12%) 1 (3%) - 
Eligibility criteria for trial participants, including 
information on how to access the list of codes and 
algorithms used to identify eligible participants, 
information on accuracy and completeness of data 
used to ascertain eligibility, and methods used to 
validate accuracy and completeness (e.g., 
monitoring, adjudication), if applicable (Modified) 
0 (0%) 5 (15%) 1 (3%) 27 (82%) 
ROUTINE-4 Describe whether and how consent was 
obtained (New) 
26 (79%) 1 (3%) 6 (18%) - 
Outcomes 6a Completely defined pre-specified primary 
and secondary outcome measures, 
including how and when they were 
assessed 
31 (94%) 2 (6%) 0 (0%) - 
Completely defined prespecified primary and 
secondary outcome measures, including how 
and when they were ascertained and the cohort 
or routinely collected database(s) used to 
ascertain each outcome (Modified) 
29 (88%) 4 (12%) 0 (0%) 0 (0%) 
ROUTINE-5 Information on how to access the list of codes 
and algorithms used to define or derive the 
outcomes from the cohort or routinely collected 
database(s) used to conduct the trial, 
information on accuracy and completeness of 
outcome variables, and methods used to 
validate accuracy and completeness (e.g., 
monitoring, adjudication), if applicable (New) 
0 (0%) 5 (15%) 27 (82%) 1 (3%) 
Allocation concealment 
mechanism 
9 Mechanism used to implement the 
random allocation sequence (such as 
sequentially numbered containers), 
describing any steps taken to conceal the 
sequence until interventions were 
assigned 
Mechanism used to implement the random 
allocation sequence (such as embedding an 
automated randomizer within the cohort or 
routinely collected database(s)), describing any 
steps taken to conceal the sequence until 
interventions were assigned (Modified) 
9 (27%) 3 (9%) 21 (64%) - 













































































































Table 2 ( continued ) 














Participant flow (a diagram 
is strongly recommended) 
13a For each group, the numbers of 
participants who were randomly 
assigned, received intended treatment, 
and were analysed for the primary 
outcome 
22 (67%) 9 (27%) 2 (6%) - 
For each group, the number of participants in 
the cohort or routinely collected 
database(s) used to conduct the trial and the 
numbers screened for eligibility, randomly 
assigned, offered and accepted interventions 
(e.g., cohort multiple RCTs), received intended 
treatment, and analysed for the primary 
outcome (Modified) 
1 (3%) 5 (15%) 1 (3%) 26 (84%) 
Discussion 
Interpretation 22 Interpretation consistent with results, 
balancing benefits and harms, and 
considering other relevant evidence 
32 (97%) 1 (3%) 0 (0%) - 
Interpretation consistent with results, balancing 
benefits and harms, and considering other 
relevant evidence, including the implications of 
using data that were not collected to answer the 
trial research questions (Modified) 
7 (21%) 1 (3%) 25 (76%) - 
Other information 
Funding 25 Sources of funding and other support 
(such as supply of drugs), role of funders 
19 (58%) 13 (39%) 1 (3%) - 
Sources of funding and other support for both 
the trial and the cohort or routinely collected 
database(s), role of funders (Modified) 
2 (6%) 20 (61%) 11 (33%) - 
I For modified items, modifications are shown in bold. For those items, only portion modified was evaluated. 
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in a majority of the trials; of 33 included studies, only one
trial reported linkage adequately. Reporting of data vali-
dation and adjudication procedures, which is necessary to
assess possible misclassification bias, was also not ade-
quately reported in most trials. Another consistent gap re-
lated to implications of using administrative data, which is
important for contextualizing trial results and understand-
ing potential limitations of using administrative data in
the trial. Finally, sources of funding for the administra-
tive database used were rarely reported. Separate studies
were conducted to evaluate reporting in trials conducted
using electronic health records [19] and registries [20] .
Similar trends were observed in those studies. In all trial
types, items related to methodological considerations in
using routinely collected data in trials, which were new
CONSORT-ROUTINE items, were not adequately reported
in most trials. 
Our review has limitations that must be taken into ac-
count. First, our scoping review was able to capture only a
sample of RCTs conducted using administrative databases
rather than all trials that have been conducted using ad-
ministrative databases. This was in part because of the lack
of accepted specific Medical Subject Headings to identify
RCTs conducted using administrative databases. In com-
bination with our inclusion criteria on what constituted an
RCT conducted using an administrative database, this led
to a relatively small sample of only 33 RCTs. It is possible
that this approach could have influenced the representative-
ness of the trials we included. For instance, we searched
for trials based on their reporting of use of administra-
tive data in the title or abstract; thus, it follows that this
item would almost always be reported in our sample of tri-
als (“Modified – Administrative database use and name in
the abstract” and “Modified – Description of trial design”).
Second, we did not extend our assessment to include study
protocols for included trials. Some authors may have in-
cluded additional study details within the protocol. How-
ever, the CONSORT extension checklist is a minimum set
of standards that should be adequately reported in reports
of trial outcomes, irrespective of having been previously
published in a protocol or in a primary trial publication in
the case of secondary reports. 
5. Conclusion 
In summary, this study was the first to assess the com-
pleteness and transparency of reporting of RCTs conducted
using administrative databases against those elements now
deemed to form a minimum reporting standard for such
studies. Although we observed CONSORT 2010 criteria
and items related to the application of the administrative
database within the RCT to be largely adequately reported,
we found a need for attention to more fulsome report-
ing of methodological conduct of these trials, mostly re-
lated to methodological aspects and implications of using
administrative databases in RCTs. The new CONSORT-Please cite this article as: M. Imran et al., Reporting transparency and complete
do not adequately report elements related to use of databases, Journal of CliniROUTINE provides guidance to improve reporting of these
types of trials. We recommend those who support, conduct,
and report trials conducted using administrative databases
to adhere to minimum reporting standards outlined in the
newly developed CONSORT-ROUTINE, in order to ensure
greater transparency and replicability and facilitate the use
of trial results in healthcare decisions. 
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Appendix 1. Electronic search strategies 
Searches were run in both MEDLINE and Cochrane
Methodology Register simultaneously. As an example, in
the registries search, lines 1–11 are the MEDLINE search
and lines 12–15 are tailored for the Cochrane Methodology
Register. The final lines of each search isolate the records
from each database, combine them so duplicate records
can be removed, then isolate the remaining records so they
can be downloaded and imported into Reference Manager
using customized import filters. 
Searches for RCTs conducted using Administrative
Databases 
1 randomized controlled trial.pt. 




6 clinical trials as topic.sh. 
7 trial.ti. 
8 or/1-7 
9 exp animals/ not humans.sh. 
0 8 not 9 
1 administrative data ∗.ab,kf,ti. 
2 healthcare data ∗.ab,kf,ti. 
3 health care data ∗.ab,kf,ti. 
4 or/11-13 
5 10 and 14 
6 (administrative adj5 data ∗).ti,ab,kw. 
7 health care data ∗.ti,ab,kw. 
8 healthcare data ∗.ti,ab,kw. 
9 or/16-18 
0 (random ∗ or RCT).ti,ab,kw. 
1 19 and 20 
2 limit 15 to yr = "2007 - 2018" 
3 22 use medall 
4 limit 21 to yr = "2007 - 2018" 
5 22 use clcmr 
Please cite this article as: M. Imran et al., Reporting transparency and complete
do not adequately report elements related to use of databases, Journal of CliniAppendix 2. Inclusion/Exclusion criteria (Title and 
Abstract) 
Exclude: not an RCT using administrative data. If
it is clear from the title and abstract that the study is not
an RCT using administrative data or is a publication on
methods or reporting of RCTs using administrative data, it
will be excluded. If it is clear from the title and abstract
that the study only reports (1) issues related to methods or
reporting of RCTs conducted using administrative data, or
(2) is a protocol from a RCT conducted using administra-
tive data, it is excluded. If the RCT involves non-human
subjects, it is excluded. Only RCTs that use administra-
tive data for conducting the trial, including activities such
as identifying eligible participants for the trial or as an
intervention or collecting trial outcomes, are eligible. 
Include: the administrative database is used for iden-
tifying eligible participants. If it is clear from the title and
abstract that the publication describes a trial in which the
administrative database was used to identify eligible trial
participants, it will be included. 
Include: the administrative database is used to as-
certain health outcomes. If it is clear from the title and
abstract that the publication describes a trial that uses ad-
ministrative data to ascertain health outcomes, as trial end-
points, it will be included. 
Inclusion/Exclusion criteria (Full-text) 
Exclude: not an RCT using administrative data. If
the study is not an RCT using administrative data or is a
publication on methods or reporting of RCTs using admin-
istrative data, it will be excluded. If the publication only
reports (1) issues related to methods or reporting of RCTs
conducted using administrative data, or (2) a protocol from
a RCT conducted using administrative data, it is excluded.
If the RCT involves non-human subjects, it is excluded.
Only RCTs that use administrative data for conducting the
trial, including activities such as identifying eligible partic-
ipants for the trial or as an intervention or collecting trial
outcomes, are eligible. 
Include: the administrative database is used for iden-
tifying eligible participants. If the publication describes
a trial in which the administrative database was used to
identify eligible trial participants, it will be included. 
Include: the administrative database is used to ascer-
tain health outcomes. If the publication describes a trial
that uses administrative data to ascertain health outcomes,
as trial endpoints, it will be included. 
Appendix 3. Coding manual for completeness and 
transparency of reporting ness in trials: Paper 3 – trials conducted using administrative databases 






























































Title and abstract 
1b Structured summary of trial 
design, methods, results, 
and conclusions (for 
specific guidance see 
CONSORT for abstracts) 
Did the authors clearly 
describe a (1) structured 
summary of (2) trial design, 
(3) methods, (4) results, 
and (5) conclusions. 
Did the authors only report 
one, two, three or four 
element(s) of this item and 
not all five elements of the 
item? 
Did the authors not 
describe a structured 
summary of trial design, 
methods, results and 
conclusions? 
Structured summary of trial 
design, methods, results, and 
conclusions (for specific 
guidance see CONSORT for 
abstracts). Specify that a cohort 
or routinely collected data were 
used to conduct the trial and, if 
applicable, provide the name of 
the cohort or routinely collected 
database(s) (Modified) 
Did the authors specify 
that a routinely collected 
database(s) was used to 
conduct the trial? 
(Sufficient to detail that an 
“administrative database 
was used”). 
Did the authors describe 
methods that would 
typically require a routinely 
collected database for 
components of the trials 
but not specify they used a 
routinely collected 
database(s)? 
Did the authors not specify 
that a routinely collected 
database(s) was used to 
conduct the trial? 
Methods 
Trial design 3a Description of trial design 
(such as parallel, factorial) 
including allocation ratio 
Did the authors clearly 
describe the trial design 
including allocation ratio? 
All other cases, where 
applicable. 
Did the authors not 
describe the trial design 
including allocation ratio? 
Description of trial design 
(such as parallel, factorial) 
including allocation ratio, that 
a cohort or routinely collected 
database(s) was used to conduct 
the trial (such as electronic 
health record, registry) and how 
the data were used within the 
trial (such as identification of 
eligible trial participants, trial 
outcomes) (Modified) 
Did the authors clearly 
mention that (1) a routinely 
collected database(s) was 
used within the trial and 
(2) how the data were used 




Did the authors only report 
one element of this item 
and not both elements of 
the item? 
Did the authors not state 
that a routinely collected 
database(s) was used 
within the trial and not 
describe how the data were 




Cohort or routinely collected database 
ROUTINE- 
1 
Name, if applicable, and 
description of the cohort or 
routinely collected database(s) 
used to conduct the trial, 
including information on the 
setting (such as primary care), 
locations, and dates, (such as 
periods of recruitment, 
follow-up, and data collection) 
(New) 
Did the authors clearly (1) 
name and (2) describe the 
routinely collected 
database(s) and (3) provide 
information on the setting, 
locations, and relevant 
dates (e.g. periods of 
recruitment, follow-up, and 
data collection)? 
Did the authors only report 
one or two element(s) of 
this item and not all three 
element s of the item? 
Did the authors not name 
and describe the routinely 
collected database(s) 
and not provide information 
on the setting, locations, 
and relevant dates (e.g. 
periods of recruitment, 
follow-up, and data 
collection)? 













































































































( continued ) 
ROUTINE- 
2 
Eligibility criteria for 
participants in the cohort or 
routinely collected database(s) 
(New) 
Did the authors clearly 
describe eligibility criteria 
for the routinely collected 
database(s)? 
All other cases, where 
applicable. 
Did the authors not 
describe all eligibility 




State whether the study 
included person-level, 
institutional-level, or other 
data linkage across two or 
more databases and, if so, 
linkage techniques and 
methods used to evaluate 
completeness and accuracy of 
linkage (New) 
Did the authors clearly 
state whether the study 
included (1) person-level, 
institutional-level, or other 
data linkage across two or 
more databases and (2) the 
methods of linkage and (3) 
methods used to evaluate 
completeness and accuracy 
of linkage? 
Did the authors only report 
one element of this item 
and not all three elements 
of the item? 
Did the authors not state 
whether the study included 
person-level, 
institutional-level, or other 
data linkage across two or 
more databases and not 
state the methods of 
linkage and methods used 
to evaluate completeness 
and accuracy of linkage? 
Trial participants 4a Eligibility criteria for 
participants 
Did the authors clearly 
describe the eligibility for 
the trial participants? 
All other cases, where 
applicable. 
Did the authors not 
describe all eligibility 
criteria for the trial 
participants? 
Eligibility criteria for trial 
participants, including 
information on how to access 
the list of codes and algorithms 
used to identify eligible 
participants, including methods 
used to assess accuracy and 
completeness, if applicable 
(Modified) 
Did the authors provide 
information on (1) how to 
access the lists of codes 
and algorithms used to 
identify participants, 
including (2) methods used 
to assess accuracy and 
completeness, if 
applicable? 
Did the authors only report 
one element of this item 
and not both elements of 
the item? 
Did the authors not provide 
information on how to 
access the lists of codes 
and algorithms used to 
identify participants, 
and not provide the 
methods used to assess 
accuracy and 
completeness? 









Describe whether and how 
consent was obtained (New) 
Did the authors describe 
clearly whether and how 
consent was obtained? 
All other cases, where 
applicable. 
Did the authors not 
describe whether and how 
consent was obtained? 
Outcomes 6a Completely defined 
pre-specified primary and 
secondary outcome 
measures, including how 
and when they were 
assessed 
Did the authors clearly 
define the pre-specified 
primary and secondary 
outcome measures, 
including how and when 
they were assessed? 
Did the authors only define 
the pre-specified primary 
and secondary outcome 
measures but not how and 
when they were assessed or 
did they describe how and 
when outcomes were 
assessed but not the 
measures? 
Did the authors not define 
the pre-specified primary 
and secondary outcome 
measures and not define 
how and when they were 
assessed? 













































































































( continued ) 
Completely defined 
pre-specified primary and 
secondary outcome measures, 
including how and when they 
were ascertained and the 
cohort or routinely collected 
database(s) used to ascertain 
each outcome (Modified) 
Did the authors clearly 
describe the routinely 
collected database(s) used 
to ascertain each outcome? 
All other cases, where 
applicable. 
Did the authors not 
describe the routinely 
collected database(s) used 
to ascertain each outcome? 









Information on how to access 
the list of codes and 
algorithms used to define or 
derive the outcomes from the 
cohort or routinely collected 
database(s) used to conduct 
the trial, including methods 
used to assess accuracy and 
completeness, if applicable 
(New) 
Did the authors clearly (1) 
describe information on 
how to access the list of 
codes and algorithms used 
to define or derive the 
outcomes from the 
routinely collected 
database(s), (2) including 
methods used to assess 
accuracy and 
completeness? 
Did the authors only report 
one element of this item 
and not both elements of 
the item? 
Did the authors not 
describe information on 
how to access the list of 
codes and algorithms used 
to define or derive the 
outcomes from the 
routinely collected 
database(s), and not 
describe the methods used 
to assess accuracy and 
completeness? 










9 Mechanism used to 
implement the random 
allocation sequence (such 
as sequentially numbered 
containers), describing any 
steps taken to conceal the 
sequence until 
interventions were assigned 
Mechanism used to implement 
the random allocation 
sequence (such as embedding 
an automated randomiser within 
the cohort or routinely collected 
database(s) ), describing any 
steps taken to conceal the 
sequence until interventions 
were assigned (Modified) 
Did the authors clearly 
describe the mechanism 
used to implement the 
random allocation 
sequence (such as 
embedding an automated 
randomiser within the 
cohort or routinely 
collected database(s)), 
describing any steps taken 
to conceal the sequence 
until interventions were 
assigned? 
All other cases, where 
applicable 
Did the authors not 
describe the mechanism 
used to implement the 
random allocation 
sequence (such as 
embedding an automated 
randomiser within the 
cohort or routinely 
collected database(s)), 
describing any steps taken 
to conceal the sequence 




(a diagram is 
strongly 
recommended) 
13a For each group, the 
numbers of participants 
who were randomly 
assigned, received 
intended treatment, and 
were analysed for the 
primary outcome 
Did the authors define 
clearly for each group, (1) 
the number of participants 
who were randomly 
assigned, (2) received 
intended treatment and (3) 
were analysed for the 
primary outcome? 
Did the authors only report 
one or two elements of this 
item and not all three 
elements of the item or 
only presented this 
information for one group? 
Did the authors not 
describe clearly for each 
group, the number of 
participants who were 
randomly assigned, and not 
received intended 
treatment and not were 
analysed for the primary 
outcome? 













































































































( continued ) 
For each group, the number of 
participants in the cohort or 
routinely collected database(s) 
used to conduct the trial and 
the numbers screened for 
eligibility, randomly assigned, 
offered and accepted 
interventions (e.g., cohort 
multiple RCTs), received 
intended treatment, and 
analysed for the primary 
outcome (Modified) 
Did the authors clearly 
define, for each group, the 
number of participants in 
the routinely collected 
database(s) used to 
conduct the trial and the 
numbers screened for 
eligibility, randomly 
assigned, received 
intended treatment, and 
analysed for the primary 
outcome? 
Did the authors only report 
some, but not all , elements 
of this item? 
Did the authors not define, 
for each group, the number 
of participants in the 
routinely collected 
database(s) used to 
conduct the trial and not 
define the numbers 
screened for eligibility, 
randomly assigned, 
received intended 
treatment, and analysed for 




with results, balancing 
benefits and harms, and 
considering other relevant 
evidence 
Did the authors clearly 
provide an interpretation 
consistent with results, 
balancing benefits and 
harms, and considering 
other relevant evidence? 
All other cases, where 
applicable 
Did the authors not provide 
an interpretation consistent 
with results, balancing 
benefits and harms, and 
considering other relevant 
evidence? 
Interpretation consistent with 
results, balancing benefits and 
harms, and considering other 
relevant evidence, including 
the implications of using data 
that were not collected to 
answer the trial research 
questions (Modified) 
Did the authors (1) clearly 
provide an interpretation 
consistent with results, 
balancing benefits and 
harms, and considering 
other relevant evidence and 
(2) describe the 
implications of using data 
that were not collected to 
answer the trial research 
questions? 
Did the authors (1) clearly 
provide an interpretation 
consistent with results, 
balancing benefits and 
harms, and considering 
other relevant evidence or 
(2) describe the 
implications of using data 
that were not collected to 
answer the trial research 
questions – but not both? 
Did the authors not provide 
an interpretation consistent 
with results, balancing 
benefits and harms, and 
considering other relevant 
evidence and not describe 
the implications of using 
data that were not 
collected to answer the 
trial research questions? 
Other 
information 
Funding 25 Sources of funding and 
other support (such as 
supply of drugs), role of 
funders 
Did the authors clearly 
describe the sources of 
funding and the role of 
funders? 
All other cases, where 
applicable 
Did the authors not 
describe the sources of 
funding and other support 
for the trial and the role of 
the funders? 
Sources of funding and other 
support for both the trial and 
the cohort or routinely collected 
database(s) , role of funders 
(Modified) 
Did the authors clearly 
describe the sources of 
funding for the database(s) 
and trial and the role of the 
funder of the trial? 
Did the authors only report 
some, but not all , elements 
of this item? 
Did the authors not 
describe the sources of 
funding for routinely 
collected database(s) and 
trial and not describe the 
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Number (%) of 
cluster randomized 
trials (n = 13) 
Number (%) of 
individually 
randomized trials 
(n = 20) 
Total (%) 
(n = 33) 
Publication type 
Primary 11 (85%) 14 (70%) 25 (76%) 
Secondary 2 (15%) 6 (30%) 8 (24%) 
Use of administrative data in trial 
Identification of patients 0 (0%) 1 (5%) 1 (3%) 
Outcome ascertainment 10 (77%) 15 (75%) 25 (76%) 
Both identification of patients and 
outcome ascertainment 
3 (23%) 4 (20%) 7 (21%) 
Administrative data used for primary 
outcome 
Yes 8 (62%) 14 (70%) 22 (67%) 
No 5 (38%) 5 (25%) 10 (30%) 
Unclear 0 (0%) 1 (5%) 1 (3%) 
Setting 
Inpatient 3 (23%) 8 (40%) 11 (33%) 
Primary care 7 (54%) 3 (15%) 10 (30%) 
Community medicine 2 (15%) 3 (15%) 5 (15%) 
Outpatient 0 (0%) 3 (15%) 3 (9%) 
Other 1 1 (8%) 3 (15%) 4 (12%) 
Country 
USA 4 (31%) 14 (70%) 18 (55%) 
Canada 3 (23%) 3 (15%) 6 (18%) 
UK 2 (15%) 2 (10%) 4 (12%) 
Europe 1 (8%) 1 (5%) 2 (6%) 
Australia 1 (8%) 0 (0%) 1 (3%) 
India 1 (8%) 0 (0%) 1 (3%) 
New Zealand 1 (8%) 0 (0%) 1 (3%) 
Disease type 
General medicine/health 7 (54%) 5 (25%) 12 (36%) 
Cardiovascular disease 3 (23%) 6 (30%) 9 (27%) 
Mental health 0 (0%) 3 (15%) 3 (9%) 
Respiratory 0 (0%) 3 (15%) 3 (9%) 
Other 2 3 (23%) 3 (15%) 6 (18%) 
Intervention 
Educational 3 (23%) 7 (35%) 10 (30%) 
Multicomponent 5 (38%) 2 (10%) 7 (21%) 
Drug 0 (0%) 4 (20%) 4 (12%) 
Guideline/reminder-based 2 (2%) 0 (0%) 2 (6%) 
Other 3 3 (23%) 7 (35%) 10 (30%) 
Comparator 
Usual care 12 (92%) 13 (65%) 25 (76%) 
Active comparator 1 (8%) 7 (35%) 8 (24%) 
Primary outcome 
Mortality 0 (0%) 5 (25%) 5 (15%) 
Hospitalization 3 (23%) 2 (10%) 5 (15%) 
( continued on next page ) 
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Surrogate 3 (23%) 1 (5%) 4 (12%) 
Self-reported 1 (8%) 2 (10%) 3 (9%) 
Other 4 5 (38%) 11 (55%) 16 (48%) 
Sample size 










1 Residential and multiple. 
2 Diabetes, cancer, potentially inapproproate medicines, drug side effects, infection, disability, homelessness. 
3 Telephone/web-based care, Family Finding program, referral, housing, health care provider support, surgical. 
4 Insurance claims, uptake of treatment, disease occurence, no primary outcome, adherence, risk of injury, multiple/composite outcomes 
and rate of injury. Appendix 6. Completeness and transparency of 
reporting for each item for RCTs conducted using 
administrative data by Primary/Secondary publication 
type (only includes original, modified and new items) Please cite this article as: M. Imran et al., Reporting transparency and complete
do not adequately report elements related to use of databases, Journal of Clininess in trials: Paper 3 – trials conducted using administrative databases 





































































Title and abstract 
1b Structured summary of trial 
design, methods, results, and 
conclusions (for specific guidance 
see CONSORT for abstracts). 
22 (80%) 3 (12%) 0 (0%) - 
Structured summary of trial design, methods, 
results, and conclusions (for specific guidance see 
CONSORT for abstracts). Specify that a cohort or 
routinely collected data were used to conduct the trial 
and, if applicable, provide the name of the cohort or 
routinely collected database(s) (Modified) 
22 (80%) 3 (12%) 0 (0%) - 
Methods 
Trial design 3a Description of trial design (such 
as parallel, factorial) including 
allocation ratio 
8 (32%) 6 (24%) 11 (44%) - 
Description of trial design (such as parallel, 
factorial) including allocation ratio, that a cohort or 
routinely collected database(s) was used to conduct 
the trial (such as electronic health record, registry) 
and how the data were used within the trial (such as 
identification of eligible trial participants, trial 
outcomes) (Modified) 







Name, if applicable, and description of the cohort 
or routinely collected database(s) used to conduct 
the trial, including information on the setting (such 
as primary care), locations, and dates, (such as 
periods of recruitment, follow-up, and data 
collection) (New) 
2 (8%) 20 (80%) 3 (12%) - 
ROUTINE- 
2 
Eligibility criteria for participants in the cohort or 
routinely collected database(s) (New) 
1 (4%) 5 (20%) 19 (76%) - 
ROUTINE- 
3 
State whether the study included person-level, 
institutional-level, or other data linkage across two 
or more databases and, if so, linkage techniques 
and methods used to evaluate completeness and 
accuracy of linkage (New) 
1 (4%) 8 (32%) 16 (64%) - 













































































































( continued ) 
Trials 
participants 
4a Eligibility criteria for participants 20 (80%) 4 (16%) 1 (4%) - 
Eligibility criteria for trial participants, including 
information on how to access the list of codes and 
algorithms used to identify eligible participants, 
information on accuracy and completeness of data 
used to ascertain eligibility, and methods used to 
validate accuracy and completeness (e.g., monitoring, 
adjudication), if applicable (Modified) 
0 (0%) 4 (16%) 0 (0%) 21 (84%) 
ROUTINE- 
4 
Describe whether and how consent was obtained 
(New) 
19 (76%) 1 (4%) 5 (20%) - 
Outcomes 6a Completely defined pre-specified 
primary and secondary outcome 
measures, including how and 
when they were assessed 
23 (92%) 2 (8%) 0 (0%) - 
Completely defined pre-specified primary and 
secondary outcome measures, including how and 
when they were ascertained and the cohort or 
routinely collected database(s) used to ascertain each 
outcome (Modified) 
21 (84%) 4 (16%) 0 (0%) 0 (0%) 
ROUTINE- 
5 
Information on how to access the list of codes and 
algorithms used to define or derive the outcomes 
from the cohort or routinely collected database(s) 
used to conduct the trial, information on accuracy 
and completeness of outcome variables, and 
methods used to validate accuracy and 
completeness (e.g., monitoring, adjudication), if 
applicable. (New) 




9 Mechanism used to implement 
the random allocation sequence 
(such as sequentially numbered 
containers), describing any steps 
taken to conceal the sequence 
until interventions were assigned 
Mechanism used to implement the random 
allocation sequence (such as embedding an 
automated randomiser within the cohort or routinely 
collected database(s)), describing any steps taken to 
conceal the sequence until interventions were 
assigned (Modified) 
8 (32%) 2 (8%) 15 (60%) - 
Results 
Participant flow 
(a diagram is 
strongly 
recommended) 
13a For each group, the numbers of 
participants who were randomly 
assigned, received intended 
treatment, and were analysed for 
the primary outcome 
17 (68%) 7 (28%) 1 (4%) - 













































































































( continued ) 
For each group, the number of participants in the 
cohort or routinely collected database(s) used to 
conduct the trial and the numbers screened for 
eligibility, randomly assigned, offered and accepted 
interventions (e.g., cohort multiple RCTs), received 
intended treatment, and analysed for the primary 
outcome (Modified) 
1 (4%) 2 (8%) 1 (4%) 21 (84%) 
Discussion 
Interpretation 22 Interpretation consistent with 
results, balancing benefits and 
harms, and considering other 
relevant evidence 
24 (96%) 1 (4%) 0 (0%) - 
Interpretation consistent with results, balancing 
benefits and harms, and considering other relevant 
evidence, including the implications of using data 
that were not collected to answer the trial research 
questions (Modified) 
5 (20%) 1 (4%) 19 (76%) - 
Other information 
Funding 25 Sources of funding and other 
support (such as supply of drugs), 
role of funders 
12 (48%) 12 (48%) 1 (4%) - 
Sources of funding and other support for both the 
trial and the cohort or routinely collected database(s), 
role of funders (Modified) 
2 (8%) 13 (52%) 40 (0%) - 
Secondary Publications, N = 8 
Title and abstract 
1b Structured summary of trial 
design, methods, results, and 
conclusions (for specific guidance 
see CONSORT for abstracts). 
7 (88%) 1 (12%) 0 (0%) - 
Structured summary of trial design, methods, 
results, and conclusions (for specific guidance see 
CONSORT for abstracts). Specify that a cohort or 
routinely collected data were used to conduct the trial 
and, if applicable, provide the name of the cohort or 
routinely collected database(s) (Modified) 
8 (100%) 0 (0%) 0 (0%) - 
Methods 
Trial design 3a Description of trial design (such 
as parallel, factorial) including 
allocation ratio 
3 (38%) 3 (38%) 2 (25%) - 













































































































( continued ) 
Description of trial design (such as parallel, 
factorial) including allocation ratio, that a cohort or 
routinely collected database(s) was used to conduct 
the trial (such as electronic health record, registry) 
and how the data were used within the trial (such as 
identification of eligible trial participants, trial 
outcomes) (Modified) 







Name, if applicable, and description of the cohort 
or routinely collected database(s) used to conduct 
the trial, including information on the setting (such 
as primary care), locations, and dates, (such as 
periods of recruitment, follow-up, and data 
collection) (New) 
1 (13%) 7 (88%) 0 (0%) - 
ROUTINE- 
2 
Eligibility criteria for participants in the cohort or 
routinely collected database(s) (New) 
1 (13%) 2 (25%) 5 (63%) - 
ROUTINE- 
3 
State whether the study included person-level, 
institutional-level, or other data linkage across two 
or more databases and, if so, linkage techniques 
and methods used to evaluate completeness and 
accuracy of linkage (New) 
0 (0%) 3 (38%) 5 (63%) - 
Trials 
participants 
4a Eligibility criteria for participants 8 (100%) 0 (0%) 0 (0%) - 
Eligibility criteria for trial participants, including 
information on how to access the list of codes and 
algorithms used to identify eligible participants, 
information on accuracy and completeness of data 
used to ascertain eligibility, and methods used to 
validate accuracy and completeness (e.g., monitoring, 
adjudication), if applicable (Modified) 
0 (0%) 1 (13%) 1 (13%) 6 (75%) 
ROUTINE- 
4 
Describe whether and how consent was obtained 
(New) 
7 (88%) 0 (0%) 1 (12%) - 
Outcomes 6a Completely defined pre-specified 
primary and secondary outcome 
measures, including how and 
when they were assessed 
8 (100%) 0 (0%) 0 (0%) - 
Completely defined pre-specified primary and 
secondary outcome measures, including how and 
when they were ascertained and the cohort or 
routinely collected database(s) used to ascertain each 
outcome (Modified) 
8 (100%) 0 (0%) 0 (0%) 0 (0%) 













































































































( continued ) 
ROUTINE- 
5 
Information on how to access the list of codes and 
algorithms used to define or derive the outcomes 
from the cohort or routinely collected database(s) 
used to conduct the trial, information on accuracy 
and completeness of outcome variables, and 
methods used to validate accuracy and 
completeness (e.g., monitoring, adjudication), if 
applicable. (New) 




9 Mechanism used to implement 
the random allocation sequence 
(such as sequentially numbered 
containers), describing any steps 
taken to conceal the sequence 
until interventions were assigned 
Mechanism used to implement the random 
allocation sequence (such as embedding an 
automated randomiser within the cohort or routinely 
collected database(s)), describing any steps taken to 
conceal the sequence until interventions were 
assigned (Modified) 
1 (13%) 1 (13%) 6 (75%) - 
Results 
Participant flow 
(a diagram is 
strongly 
recommended) 
13a For each group, the numbers of 
participants who were randomly 
assigned, received intended 
treatment, and were analysed for 
the primary outcome 
5 (63%) 2 (25%) 1 (13%) - 
For each group, the number of participants in the 
cohort or routinely collected database(s) used to 
conduct the trial and the numbers screened for 
eligibility, randomly assigned, offered and accepted 
interventions (e.g., cohort multiple RCTs), received 
intended treatment, and analysed for the primary 
outcome (Modified) 
0 (0%) 3 (38%) 0 (0%) 5 (63%) 
Discussion 
Interpretation 22 Interpretation consistent with 
results, balancing benefits and 
harms, and considering other 
relevant evidence 
8 (100%) 0 (0%) 0 (0%) - 
Interpretation consistent with results, balancing 
benefits and harms, and considering other relevant 
evidence, including the implications of using data 
that were not collected to answer the trial research 
questions (Modified) 
2 (25%) 0 (0%) 6 (75%) - 
Other information 
Funding 25 Sources of funding and other 
support (such as supply of drugs), 
role of funders 
7 (88%) 1 (13%) 0 (0%) - 
Sources of funding and other support for both the 
trial and the cohort or routinely collected database(s), 
role of funders (Modified) 
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